205 completed, 58 terminated, 31 unknown, 30 recruiting. 360 Phase 1, 122 Phase 2.
Follow Rectal Neoplasms: new trials by email Literature Review of Rectal Neoplasms trials Research Report on Rectal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody) - Rectal Cancer Patients | Phase 1 | Recruiting | Henry Smith | 20 | 2026-10-23 | 2026-11-04 |
| A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer DEM301 - Metastatic Colorectal Cancer, Colon Cancer | Phase 1 | Recruiting | DEM BioPharma, Inc. | 60 | 2026-10-01 | 2026-10-28 |
| Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial Arginine-Deprived Diet, Short-Course Radiotherapy (SCRT), CAPOX + PD-1 Inhibitor - Rectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 140 | 2026-08-14 | 2026-08-10 |
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations BLU-924 - Advanced Solid Tumor, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Blueprint Medicines Corporation | 265 | 2026-06-04 | 2026-09-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations INV-8989 - Advance Solid Tumors, Colon and Rectal Cancer | Phase 1 / Phase 2 | Recruiting | Shenzhen Ionova Life Sciences Co., Ltd. | 178 | 2026-06-01 | 2026-06-10 |
| A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab - KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Kestrel Therapeutics, Inc. | 545 | 2026-04-21 | 2026-11-12 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas EVOLVE104 - Bladder Cancer, Squamous Cell Carcinoma of the Lung | Phase 1 | Recruiting | EvolveImmune United, Inc | 160 | 2025-11-13 | 2026-09-15 |
| Adaptive Radiation Boost for Rectal Cancer Adaptive Radiotherapy Boost - Rectum Cancer, Adenocarcinoma | Phase 1 | Recruiting | Fox Chase Cancer Center | 37 | 2025-10-24 | 2025-12-09 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK5460025 - Neoplasms, Colorectal, Neoplasms | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 47 | 2025-10-20 | 2026-09-16 |
| CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors CEA-targeted CAR-T cells - Lung Cancer, Gastric Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 108 | 2025-09-12 | 2025-10-02 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial Biospecimen Collection, Computed Tomography, Consolidation Therapy - Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 36 | 2025-04-07 | 2026-07-22 |
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients Rifaximin 550 MG, Standard Care Chemoradiation - Radiotherapy Induced Diarrhea, Acute Radiation Enteritis | Phase 1 / Phase 2 | Not yet recruiting | Mansoura University | 80 | 2025-01-20 | 2025-01-20 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
Showing 20 of 360. Sign in to see all of them.
Colonic Neoplasms (213) · Colorectal Neoplasms (153) · Pancreatic Neoplasms (71) · Anus Neoplasms (68) · Stomach Neoplasms (56) · Carcinoma, Non-Small-Cell Lung (53) · Breast Neoplasms (47) · Uterine Cervical Neoplasms (44) · Esophageal Neoplasms (39) · Neoplasms (36) · Lung Neoplasms (35) · Squamous Cell Carcinoma of Head and Neck (32) · Carcinoma, Renal Cell (31) · Endometrial Neoplasms (31)
Digestive System Diseases (358) · Intestinal Diseases (358) · Rectal Diseases (358) · Digestive System Neoplasms (357) · Gastrointestinal Diseases (357) · Neoplasms by Site (356) · Intestinal Neoplasms (353) · Gastrointestinal Neoplasms (349) · Neoplasms (324) · Colonic Diseases (235) · Colorectal Neoplasms (207) · Neoplasms by Histologic Type (104) · Urogenital Diseases (94) · Neoplasms, Glandular and Epithelial (92) · Urogenital Neoplasms (89)
Fluorouracil (57) · Oxaliplatin (51) · Capecitabine (49) · Leucovorin (39) · Radiotherapy (34) · Irinotecan (31) · Bevacizumab (21) · Cetuximab (20) · pembrolizumab (15) · Cyclophosphamide (14) · Radiation (14) · Gemcitabine (12) · fludarabine (9) · Erlotinib Hydrochloride (8) · Carboplatin (7)
National Cancer Institute (NCI) (49) · Memorial Sloan Kettering Cancer Center (17) · City of Hope Medical Center (12) · M.D. Anderson Cancer Center (9) · Jonsson Comprehensive Cancer Center (6) · Roswell Park Cancer Institute (6) · Case Comprehensive Cancer Center (5) · Fox Chase Cancer Center (5) · Chongqing Precision Biotech Co., Ltd (4) · Gilead Sciences (4) · Novartis Pharmaceuticals (4) · Swiss Cancer Institute (4) · UNC Lineberger Comprehensive Cancer Center (4) · University of Texas Southwestern Medical Center (4) · Amgen (3)
United States (258) · China (27) · United Kingdom (17) · Canada (16) · Germany (14) · Spain (14) · Australia (12) · France (10) · Japan (10) · Belgium (9) · Netherlands (9) · Italy (8) · Switzerland (8) · South Korea (7) · Sweden (6)
Sydney Welt, MD (5) · Anthony W. Tolcher, MD (3) · Marwan Fakih, MD (3) · Marwan G Fakih (3) · Nancy E. Kemeny, MD (3) · William Schelman (3) · Charalampos Floudas, M.D. (2) · Deborah E Citrin, M.D. (2) · Derek Jonker, MD (2) · Eric X. Chen, MD, PhD (2) · Herbert K. Lyerly, MD (2)
PMID 10496568, PMID 11919232, PMID 11919233, PMID 12196376, PMID 12393999, PMID 12576903, PMID 14981738, PMID 16009951, PMID 16062074, PMID 17026790, PMID 17216531, PMID 17520255, PMID 17985341, PMID 18398152, PMID 18470481, PMID 18493824, PMID 18519811, PMID 18565686, PMID 18809314, PMID 19228749, PMID 19233901, PMID 1929133, PMID 19372041, PMID 19525947, PMID 19602035, PMID 19735988, PMID 20068553, PMID 20179219, PMID 20234350, PMID 20523092, PMID 21367608, PMID 21895536, PMID 23670746, PMID 23838996, PMID 24285980, PMID 24356623, PMID 24943235, PMID 24987057, PMID 25117066, PMID 25612635, PMID 25772756, PMID 25965900, PMID 26049686, PMID 26062933, PMID 26310534, PMID 26597443, PMID 26611425, PMID 26861740, PMID 27044938, PMID 27075016
P30CA033572 (6), P30CA014520 (3), P30CA016056 (3), P30CA043703 (3), U01CA062490 (3), U01CA062491 (3), 2016 (2), 2019 (2), 2025 (2), P30CA006927 (2), P30CA012197 (2), P30CA015083 (2), P30CA016087 (2), P30CA054174 (2), P30CA068485 (2)